Intest Res Search

CLOSE


Published online February 3, 2023.
Are the incidence rates of hospitalized infections, herpes zoster, and malignancies different depending on treatment drugs in patients with ulcerative colitis?
Incidence rates for hospitalized infections, herpes zoster, and malignancies in patients with ulcerative colitis in Japan: an administrative health claims database analysis

Katsuyoshi Matsuoka, Kanae Togo, Noritoshi Yoshii, Masato Hoshi, Shoko Arai. Intest Res. 2023;21(1):88-89


Although immunosuppressants and biologics are drugs that contribute to improving the prognosis of ulcerative colitis (UC) by inducing mucosal healing, these drugs can cause an increase in opportunistic infections by weakening the host immune responses. In addition, these drugs have the potential to increase the risk of developing malignancies.

The present study examined the incidence of hospitalized infections, herpes zoster (HZ), and malignancies in patients with UC, stratified by treatment using Japanese administrative health claims databases.

  1. Incidence rates (IRs) of hospitalized infections, HZ, and malignancies were generally similar among patients receiving immunosuppressants (azathioprine and 6-mercaptopurine), tumor necrosis factor inhibitors (TNFi), and combination therapy (immunosuppressants and TNFi).
  2. Incidence rates (IRs) of hospitalized infections, HZ, and malignancies were numerically higher in patients receiving calcineurin inhibitors (tacrolimus and cyclosporine) compared with immunosuppressants or tumor TNFi.
  3. The numerically higher incidence rates of hospitalized infections, HZ, and malignancies in patients with UC receiving calcineurin inhibitors suggests the importance of close monitoring of patients during the calcineurin inhibitor treatment.
Read more about the incidence of hospitalized infections, HZ, and malignancies in patients with UC, stratified by treatment.

Best regards,
Related article
  • Journal Impact Factor 4.9
  • SCImago Journal & Country Rank
  • AOCC 2018
  • CSIBD
  • JSIBD
  • kasid
  • TSIBD
  • CCF
  • PubMed Central
  • PubMed
  • KoreaMed
  • KoMCI
  • Scopus
  • Directory of Open Access Journals (DOAJ)
  • GoogleScholar
  • EBSCO
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • ORCID
  • COPE
  • KOFST
  • TrendMD


ABOUT
ARTICLE & TOPICS
Article Category

Browse all articles >

TOPICS

Browse all articles >

BROWSE ARTICLES
EDITORIAL POLICY
AUTHOR INFORMATION
Editorial Office
Room 310, Lotte Gold Rose II, 31 Seolleung-ro 86-gil, Gangnam-gu, Seoul 06193, Korea
Tel: +82-2-957-6145    Fax: +82-2-957-6146    E-mail: thekasid@irjournal.org                

Copyright © 2024 by Korean Association for the Study of Intestinal Diseases.

Developed in M2PI

Close layer
prev next